Business · Companies · 5 hrs ago
Oncolytics reports new patent protection for pelareorep
Oncolytics Biotech is a clinical-stage immunotherapy company developing pelareorep, a treatment it is studying for cancer.
The company says patents covering pelareorep’s use as an immunotherapy have been issued in several countries.
It expects a U.S. patent to be issued in the near term.
Three other patent applications are pending, including two covering how the treatment is used.
The company expects one of those applications to move to a faster review process this quarter.
It also plans to seek a patent for a modified, next-generation version of pelareorep.
Existing manufacturing patent protection runs through 2044, and the company says its new patent efforts aim to protect certain uses and future innovations into the late 2040s, depending on patents being granted and their terms.
Oncolytics Biotech said it has secured patent protection in several countries for a new method of using pelareorep as a cancer immunotherapy.
The company said U.S. issuance of the patent is expected in the near term.
It said the new protection, together with existing manufacturing patents, is intended to cover specified therapeutic uses into the late 2040s, subject to patent issuance and applicable terms.
Oncolytics also reported three pending patent applications and plans to seek composition-of-matter protection for a modified version of pelareorep.
- Who
- Oncolytics Biotech, a clinical-stage immunotherapy company developing pelareorep.
- What
- The company reported patent protection for a new method of using pelareorep as a cancer immunotherapy and gave an update on its intellectual property portfolio.
- When
- October 12, 2026.
- Where
- The announcement was issued from San Diego.
- Why
- The company said the initiatives are intended to extend protection for specified therapeutic uses and future innovations into the late 2040s.
This story does not have two clearly opposing sides.
This story does not have a timeline yet.
- Patent protection
- New method-of-use patent issued in several countries
- U.S. patent
- Issuance expected in the near term
- Existing manufacturing protection
- Through 2044
- Pending applications
- Three, including two method-of-use applications
- Future protection
- Company expects to add a composition-of-matter patent for modified “next generation” pelareorep
Sources
Related news
White Cliff finds visual copper sulphides in new Rae project target
Canada could use helium-3 supply in future trade talks with the US
Toronto startup tests robotic surgical arm in first human operation
Canada loses 68,000 jobs in September as unemployment rate rises to 6.5%
Canada plans new support to help trades apprentices complete training
Stelco disputes Ottawa’s claims as layoffs threaten hundreds of jobs
Stelco says it will proceed with Ontario layoffs despite Ottawa's warning
Koho rejects prediction markets as it nears bid for Canadian bank licence
Gallant adds term loan commitments to support Lumileds
Capital Power CEO urges Alberta voters to remain in Canada
Competition at home is vital to attracting investment, says Competition Bureau's Pratt
